New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

In a groundbreaking study, scientists have identified a gut microbe, Bacteroides vulgatus, and its metabolites as potential ...

WEIGHT loss drugs are still being brazenly flogged on the black market by a celebrity hairdresser who gave The Sun a Mounjaro ...

Ozempic users who suffer strokes appear to have much lower death rates and better long-term survival. Evidence points to a ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach? Medical experts weigh in.

Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...